Interleukin-2-regulatory T cell axis critically regulates maintenance of hematopoietic stem cells
dc.contributor.author | Giampaolo, S | |
dc.contributor.author | Wójcik, G | |
dc.contributor.author | Serfling, E | |
dc.contributor.author | Patra, AK | |
dc.date.accessioned | 2018-05-14T13:08:36Z | |
dc.date.issued | 2017-03-18 | |
dc.identifier.issn | 1949-2553 | |
dc.identifier.issn | 1949-2553 | |
dc.identifier.uri | http://hdl.handle.net/10026.1/11501 | |
dc.description.abstract |
The role of IL-2 in HSC maintenance is unknown. Here we show that Il2-/- mice develop severe anomalies in HSC maintenance leading to defective hematopoiesis. Whereas, lack of IL-2 signaling was detrimental for lympho- and erythropoiesis, myelopoiesis was enhanced in Il2-/- mice. Investigation of the underlying mechanisms of dysregulated hematopoiesis in Il2-/- mice shows that the IL-2-Treg cell axis is indispensable for HSC maintenance and normal hematopoiesis. Lack of Treg activity resulted in increased IFN-γ production by activated T cells and an expansion of the HSCs in the bone marrow (BM). Though, restoring Treg population successfully rescued HSC maintenance in Il2-/- mice, preventing IFN-γ activity could do the same even in the absence of Treg cells. Our study suggests that equilibrium in IL-2 and IFN-γ activity is critical for steady state hematopoiesis, and in clinical conditions of BM failure, IL-2 or anti-IFN-γ treatment might help to restore hematopoiesis. | |
dc.format.extent | 29625-29642 | |
dc.format.medium | ||
dc.language | en | |
dc.language.iso | en | |
dc.publisher | Impact Journals, LLC | |
dc.subject | hematopoietic stem cells | |
dc.subject | IL-2 | |
dc.subject | Treg cells | |
dc.subject | IL-10 | |
dc.subject | IFN-gamma | |
dc.subject | Immunology and Microbiology Section | |
dc.subject | Immune response | |
dc.subject | Immunity | |
dc.title | Interleukin-2-regulatory T cell axis critically regulates maintenance of hematopoietic stem cells | |
dc.type | journal-article | |
dc.type | Article | |
plymouth.author-url | https://www.ncbi.nlm.nih.gov/pubmed/28415569 | |
plymouth.issue | 18 | |
plymouth.volume | 8 | |
plymouth.publication-status | Published online | |
plymouth.journal | Oncotarget | |
dc.identifier.doi | 10.18632/oncotarget.16377 | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/Faculty of Health/Peninsula Medical School | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine | |
plymouth.organisational-group | /Plymouth/Users by role | |
plymouth.organisational-group | /Plymouth/Users by role/Academics | |
dc.publisher.place | United States | |
dcterms.dateAccepted | 2017-03-06 | |
dc.identifier.eissn | 1949-2553 | |
dc.rights.embargoperiod | No embargo | |
rioxxterms.versionofrecord | 10.18632/oncotarget.16377 | |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2017-03-18 | |
rioxxterms.type | Journal Article/Review | |
plymouth.oa-location | http://10.0.72.200/oncotarget.16377 |